Animal models in influenza vaccine testing

Expert Review of Vaccines

Volumn 7, Issue 6, 2008, Pages 783-793

  Van Der Laan, Jan Willem ^a   Herberts, Carla ^a   Lambkin Williams, Robert ^b   Boyers, Alison ^b   Mann, Alexander J ^b   Oxford, John ^b  

^a NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

Author keywords

Animal model; Disease end point; Ferret; Influenza vaccine; Macaque; Mouse; Pandemic

Indexed keywords

INFLUENZA VACCINE;

DRUG EFFECT; EPIDEMIC; FERRET; INFLUENZA; INFLUENZA VACCINATION; INFLUENZA VIRUS A H2N2; INFLUENZA VIRUS A H5N1; MACACA; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW;

ANIMALS; FERRETS; HUMANS; INFLUENZA VACCINES; MACACA; MICE; MODELS, ANIMAL; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 49449117372     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.6.783     Document Type: Review

References (76)

1. Hinshaw VS. Influenza in other species (seal, whale and mink). In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science Ltd, Oxford, UK 163-167 (1998).
2. Smith W, Andrewes CH, Laidlaw PP. A virus obtained from influenza patients. Lancet ii, 66-68 (1933).
3. Webster RG, Govorkova E. Influenza-continuing evolution and spread. N. Engl. J. Med. 355, 2174-2177 (2006).
4. Van Reeth K. Avian and swine influenza viruses: our current understanding of the zoonotic risk. Vet. Res. 38, 243-260 (2007).
5. Houff SA, Miller GL, Lovell CR et al. The Guillain-Barré syndrome and swine influenza vaccination. Trans. Amer. Neurol. Soc. 102, 120-123 (1977).
6. Van Reeth K, Nauwynck H, Pensaert M. Bronchoalveolar interpheron-α, tumor necrosis factor-α, interleukin-1, and inflammation during acute influenza in pigs: a possible model for humans? J. Infect. Dis. 177, 1076-1079 (1998).
7. Van Reeth K, Van Gucht S, Pensaert M. Correlations between lung proinflammatory cytokine levels, virus replication, and disease after swine influenza virus challenge of vaccination-immune pigs. Viral Immunol. 15, 583-594 (2002).
8. Solorzano A, Webby RJ, Lager KM et al. Mutations in the NS1 protein of swine influenza virus impair anti-interferon activity and confer attenuation in pigs. J. Virol. 79, 7535-7543 (2005).
9. Scholtissek C, Hinshaw VS, Olsen CW. Influenza in pigs and their role as the intermediate host. In: Textbook of Influenza. Nicholson KG, Webster RG, Hay AJ (Eds). Blackwell Science Ltd, Oxford, UK 137-145 (1998).
10. Ito T, Couceiro JN, Kelm S et al. Molecular basis for the generation in pigs of influenza A viruses with pandemic potential. J. Virol. 72, 7367-7373 (1998).
11. Shinya K, Ebina M, Yanada S et al. Influenza virus receptors in the human airway. Nature 440, 435-436 (2006).
12. Hirst GK. Studies on the mechanism of adaptation of influenza virus to mice. J. Exp. Med. 86, 357-366 (1947).
13. Subbarao K, Luke C. H5N1 viruses and vaccines. PLoS Pathog. 3, 40 (2007).
14. Maines TR, Lu XH, Erb SM et al. Avian influenza (H5N1) viruses isolated from humans in Asia in 2004 exhibit increased virulence in mammals. J. Virol. 79(18), 11788-11800 (2005)
15. Sidwell RW, Smee DF. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antiviral Res. 48, 1-16 (2000).
16. van Riel D, Munster VJ, de Wit E et al. Human and avian influenza viruses target different cells in the lower respiratory tract of humans and other mammals. Am. J. Pathol. 171, 1215-1223 (2008).
17. Ward AC. Virulence of influenza A virus for mouse lung. Virus Genes 14, 187-194 (1997).
18. Sidwell RW. The mouse model of influenza virus infection: In: Handbook of Animal Models of Infection. Zak O (Ed.). Academic Press, CA, USA 981-987 (1999).
19. Burleson GR, Burleson FG. Influenza virus host resistance model. Methods 41(1), 31-37 (2007).
20. Van Reeth K. Cytokines in the pathogenesis of influenza. Vet. Microbiol. 74(1-2), 109-116 (2000).
21. Schulman JL. The use of an animal model to study transmission of influenza virus infection. Am. J. Public Health Nations Health 58, 2092-2096 (1968).
22. Tamura S, Tanimoto T, Kurata T. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn. J. Infect. Dis. 58(4), 195-207 (2005).
23. Sidwell RW, Smee DF. Experimental disease models of influenza virus infections: recent developments. Drug Discov. Today Dis. Models 1, 57-63 (2004).
24. Minne A, Jaworska J, Gerhold K et al. Intranasal delivery of whole influenza vaccine prevents subsequent allergen-induced sensitization and airway hyperreactivity in mice. Clin. Exp. Allergy 37, 1250-1258 (2007).
25. Sharpe M, Lynch D, Topham S et al. Protection of mice from H5N1 influenza challenge by prophylactic DNA vaccination using particle mediated epidermal delivery. Vaccine 25(34), 6392-6398 (2007).
26. Lebrec H, Burleson GR. Influenza virus host resistance models in mice and rats: utilization for immune function assessment and immunotoxicology. Toxicology 91(2), 179-188 (1994).
27. Armerding D, Rossiter H, Ghazzouli I, Liehl E. Evaluation of live and inactivated influenza A virus vaccines in a mouse model. J. Infect. Dis. 145(3), 320-330 (1982).
28. Lu X, Renshaw M, Tumpey TM et al. Immunity to influenza A H9N2 viruses induced by infection and vaccination. J. Virology 75(10), 4896-4901 (2001).
29. Desheva JA, Lu XH, Rekstin AR et al. Characterization of an influenza A H5N2 reassortant as a candidate for live-attenuated and inactivated vaccines against highly pathogenic H5N1 viruses with pandemic potential. Vaccine 24, 6859-6866 (2006).
30. Ichinohe T, Tamura S, Kawaguchi A et al. Cross-protection against H5N1 influenza virus infection is afforded by intranasal inoculation with seasonal trivalent inactivated influenza vaccine. J. Infect. Dis. 196, 1313-1320 (2007).
31. Zanvit P, Havlícková M, Tácner J et al. Protective and cross-protective mucosal immunization of mice by influenza virus type A with bacterial adjuvant. Immunol. Lett. 115, 144-152 (2008).
32. Smith W, Andrewes CH, Laidlow PP. Influenza: experiments on the immunisation of ferrets and mice. Br. J. Exp. Pathol. 16, 291-302 (1937).
33. Smith W, Stuart-Harris CH. Influenza infection of man from the ferret. Lancet 2, 121 (1936).
34. Burnet FM, Clarke E. Influenza: a survey of the last 50 years in the light of modern work on the virus of epidemic influenza. Monographs Res. Med. 4, 1-118 (1942).
35. Andrewes CH, Glover RE. Spread of infection from the respiratory tract of the ferret. Transmission of influenza A virus. Br. J. Exp. Pathol. 22, 91-97 (1941).
36. Herlocher ML, Elias S, Truscan R et al. Ferrets as a transmission model for influenza: sequence changes in HA1 of type A (H3N2) virus. J. Inf. Dis. 184, 542-526 (2001).
37. Hers JF, Mulder J. Broad aspects of the pathology and pathogenesis of human influenza. Amer. Rev. Resp. Dis. 83, 54 (1961).
38. Smith W, Andrewes CH, Stuart-Harris CH. A study of epidemic influenza with special reference to the 1936-7 epidemic. studies on immunisation of ferrets and mice. Med. Res. Council (Brit.) Spec. Rep. Series 228, 125-127 (1938).
39. Stuart-Harris CH. Influenza and Other Virus Infections of the Respiratory Tract. Edward Arnold, London, UK 235 (1953).
40. Rennie P, Bowtell P, Hull D et al. Low pH gel sprays inactivate influenza viruses in vitro and protect ferrets against influenza infection. Resp. Res. 8, 38-45 (2007).
41. Ives JA, Carr JA, Mendel DB et al. The H274Y mutation in the influenza A (H1N1) neuraminidase active site following oseltamivir phosphate treatment leaves virus severely compromised both in vitro and in vivo. Antiviral. Res. 55, 307 (2002).
42. Smith H, Sweet C. Lessons for human influenza from pathogenicity studies with ferrets. Rev. Inf. Dis. 10, 56-75 (1988).
43. Zitzow LA, Rowe T, Morken T et al. Pathogenesis of avian influenza A (H5N1) viruses in ferrets. J. Virol. 76, 4420-4429 (2002).
44. Ochi A, Danesh A, Seneviratne C et al. Cloning, expression and immunoassay detection of ferret IFN-γ . Dev. Comp. Immunol. 32(8), 890-897 (2008).
45. Stuart Harris CH, Andrewes CH, Smith W. A study of epidemic influenza with special reference to the 1936-37 epidemics. Med. Res. Council (Brit.) Special Report Series 22 (1938).
46. Baras B, Stittelaar KJ, Simon JH et al. Cross-protection against lethal H5N1 challenge in ferrets with an adjuvanted pandemic influenza vaccine. PloS One 3(1), e1401 (2008).
47. Reuman, PD, Keely S, Schiff GM. Assessment of signs of influenza illness in the ferret model. J. Virol. Methods 24, 27-34 (1989).
48. Lambkin-Williams R, Herog C, Viret JF et al. Strong local and systemic protective immunity inducing the ferret model by an intranasal virosome formulated influenza sub unit vaccine. Vaccine 22, 4930-4996 (2004).
49. Mann A, Marriott AC, Balasingam S et al. Interfering vaccine (defective interfering influenza A virus) protects ferrets from influenza and allows them to develop solid immunity. Vaccine 24, 4290-4296 (2006).
50. Fenton RJ, Clark A, Potter CW. Comparative immunity following infection and immunity with live or inactivated vaccine. Br. J. Exp. Path. 62, 297-307 (1981).
51. Govorkova EA, Rehg JE, Krauss S et al. Lethality to ferrets of H5N1 influenza viruses isolated from humans and poultry in 2004. J. Virol. 79, 2191-2198 (2005).
52. Hampson AW. Ferrets and the challenges of H5N1 vaccine formulation. J. Infect. Dis. 194, 143-145 (2006).
53. Hui Ling Yen, Lipatov AS, Ilyushina NA et al. Inefficient transmission of H5N1 influenza viruses in a ferret contact model. J. Virol. 81(13), 6890-6898 (2007).
54. Govorkova EA, Webby RJ, Humberd J et al. Immunization with reverse genetics produced H5N1 influenza vaccine protects ferrets against homologous and heterogous challenge. J. Infect. Dis. 194, 159-167 (2006).
55. Lipatov AS, Hoffmann E, Salomon R et al. Cross-protectiveness and immunogenicity of influenza A/Duck/Singapore/3/97 (H5) vaccines against infection with A/Vietnam/1203/04 (H5N1) virus in ferrets. J. Infect. Dis. 194, 1040-1043 (2006).
56. Ferguson NM, Cummings, DA, Fraser C et al. Strategies for mitigating an influenza pandemic. Nature 442, 448-452 (2006).
57. Germann TC, Kadau K, Longini IM Jr et al. Mitigation strategies for pandemic influenza in the United States. Proc. Natl Acad. Sci. USA 103, 5935-5940 (2006).
58. Rimmelzwaan GF, Baars M, Van Beek R et al. Induction of protective immunity against influenza virus in a macaque model: comparison of conventional and iscom vaccines. J. Gen. Virol. 78, 757-765 (1997).
59. Villinger F, Miller R, Mori K et al. IL-15 is superior to IL-2 in the generation of long-lived antigen specific memory CD4 and CD8 T cells in rhesus macaques. Vaccine 22, 3510-3521 (2004).
60. Baskin CRA, Garcia-Sastre A, Tumpey TM et al. Integration of clinical data, pathology, and DNA microarrays in influenza virus-infected pigtailed macaques (Macaca nemestrina). J. Virol. 78, 10420-10432 (2004).
61. Kobasa D, Jones SM, Shinya K et al. Aberrant innate immune response in lethal infection of macaques with the 1918 influenza virus. Nature 445, 319-323 (2007).
62. Rimmelzwaan GF, Kuiken T, Van Amerongen G et al. Pathogenesis of influenza A (H5N1) virus infection in a primate model. J. Virol. 75(14), 6687-6691 (2001).
63. Hubby B, Talarico T, Maughan M et al. Development and preclinical evaluation of an αvirus replicon vaccine for influenza. Vaccine 25, 8180-8189 (2007).
64. Baas T, Baskin CR, Diamond DL et al. Integrated molecular signature of disease: analysis of influenza virus-infected macaques through functional genomics and proteomics. J. Virol. 80(21), 10813-10828 (2006).
65. Ruat, Caillet C, Bidaut et al. Vaccination of macaques with adjuvanted formalin-inactivated influenza A (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J. Virol. 82, 2565-2569 (2008).
66. Itoh Y, Ozaki H, Tsuchiya et al. A vaccine prepared from a non-pathogenic H5N1 avian influenza virus strain confers protective immunity against highly pathogenic avian influenza virus infection in cynomolgus macaques. Vaccine 26, 562-572 (2008).
67. Fornek JL, Korth MJ, Katze MG. Use of functional genomics to understand influenza-host interactions. Adv. Virus Res. 70, 81-100 (2007).
68. Lowen AC, Mubareka S, Tumpey TM et al. The guinea pigs as a transmission model for human influenza viruses. Proc. Natl Acad. Sci. USA 103, 9988-9992 (2006).
69. Van Riel D, Munster VJ, De Wit E et al. H5N1 virus attachment to lower respiratory tract. Science 312, 399 (2006).
70. Medical Research Committee. Special report series no. 36. Studies of influenza in hospitals of the British armies in France. HM Stationary Office, London, UK (1919).
71. Report on the pandemic of influenza 1918-1919. Reports on the public health and medical subjects, no. 4. HM Stationary Office, London, UK (1920).
72. Scientific Steering Committee, DG Health and Consumer Protection. The need for nonhuman primates in biomedical research. Statement of the Scientific Steering Committee adopted at its meeting of 4-5 April 2002 www.ec.europa.eu
73. Note for guidance on preclinical pharmacological and toxicological testing of vaccines www.emea.europa.eu/pdfs/human/swp/046595en.pdf
74. WHO guideline on nonclinical evaluation of vaccines: November (2003) www.who.int
75. Impact of the Göttingen minipig in toxicity assessment www.rethink-eu.dk
76. The Medical Front WWI. Influenza pandemic of 1918-1919. The pathology of influenza in France by Dr SW Patterson www.vlib.us/medical